Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 6/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.38 |
| ▸ | TDO2 | P48775 | 3/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067984 | 0.75 | MTNR1A (0.43) | FEN1EGLN1 | |
| SCHEMBL4062961 | 0.75 | CNR1 (0.45) | FEN1EGLN1 | |
| SCHEMBL4066741 | 0.72 | EGLN1 (0.69) | FEN1EGLN1 | |
| SCHEMBL5227092 | 0.72 | SMN1; SMN2 (0.51) | FEN1ALDH1A1EGLN1KDM4E | |
| SCHEMBL966559 | 0.71 | FEN1 (0.52) | FEN1ALDH1A1EGLN1KDM4E | |
| SCHEMBL4058387 | 0.71 | EGLN1 (0.70) | FEN1EGLN1 | |
| SCHEMBL4064351 | 0.71 | FEN1 (0.53) | FEN1ALDH1A1EGLN1 | |
| SCHEMBL5778708 | 0.70 | FEN1 (0.53) | FEN1ALDH1A1EGLN1 | |
| SCHEMBL4069538 | 0.70 | EGLN1 (0.51) | FEN1EGLN1 | |
| SCHEMBL4057517 | 0.70 | ADORA2A (0.53) | FEN1EGLN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | claimed |
| US-6919351-B2 | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | claimed |
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | claimed |
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | claimed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-6919351-B2 | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | disclosed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | POLI, DUT, NAAA | GSK3B 1997/4885FEN1 511/4885ALDH1A1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.